6286
´
E.F. Silva et al. / Vaccine 25 (2007) 6277–6286
[9] Haake DA, Dundoo M, Cader R, Kubak BM, Hartskeerl RA, Sejvar JJ,
et al. Leptospirosis, water sports, and chemoprophylaxis. Clin Infect
Dis 2002;34(9):e3–40.
[10] Ricaldi JN, Vinetz JM. Leptospirosis in the tropics and in travelers.
Curr Infect Dis Rep 2006;8(1):51–8.
[11] Meites E, Jay MT, Deresinski S, Shieh WJ, Zaki SR, Tompkins
L, et al. Reemerging leptospirosis, California. Emerg Infect Dis
2004;10(3):406–12.
[12] Vinetz JM, Glass GE, Flexner CE, Mueller P, Kaslow DC. Sporadic
urban leptospirosis. Ann Intern Med 1996;125(10):794–8.
[13] McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin
Infect Dis 2005;18(5):376–86.
[14] Ko AI, Galvao Reis M, Ribeiro Dourado CM, Johnson Jr WD,
Riley LW. Urban epidemic of severe leptospirosis in Brazil. Lancet
1999;354(9181):820–5.
[15] Sarkar U, Nascimento SF, Barbosa R, Martins R, Nuevo H, Kalafanos
I, et al. Population-based case-control investigation of risk factors
for leptospirosis during an urban epidemic. Am J Trop Med Hyg
2002;66(5):605–10.
[16] Johnson MA, Smith H, Joeph P, Gilman RH, Bautista CT, Campos KJ,
et al. Environmental exposure and leptospirosis, Peru. Emerg Infect Dis
2004;10(6):1016–22.
[17] Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine
2006;24(31–32):5787–99.
[18] Moore GE, Guptill LF, Glickman NW, Caldanaro RJ, Aucoin D, Glick-
man LT. Canine leptospirosis, United States, 2002–2004. Emerg Infect
Dis 2006;12(3):501–3.
[19] Adler B, Faine S. Immunogenicity of boiled compared with formalized
leptospiral vaccines in rabbits, hamsters and humans. J Hyg (Lond)
1980;84(1):1–10.
[20] Freudenstein H, Hein B. Potency of leptospiral vaccines and protection
against chronic infection in golden hamsters. Comp Immunol Microbiol
Infect Dis 1991;14(3):229–34.
[21] Thiermann AB. Leptospirosis: current developments and trends. J Am
Vet Med Assoc 1984;184(6):722–5.
[22] Sonrier C, Branger C, Michel V, Ruvoen-Clouet N, Ganiere JP, Andre-
Fontaine G. Evidence of cross-protection within Leptospira interrogans
in an experimental model. Vaccine 2000;19(1):86–94.
[23] Bolin CA, Zuerner RL, Trueba G. Effect of vaccination with a pen-
tavalent leptospiral vaccine containing Leptospira interrogans serovar
hardjo type hardjo-bovis on type hardjo-bovis infection of cattle. Am
J Vet Res 1989;50(12):2004–8.
[24] Midwinter A, Faine S, Adler B. Vaccination of mice with lipopolysac-
charide (LPS) and LPS-derived immuno-conjugates from Leptospira
interrogans. J Med Microbiol 1990;33(3):199–204.
[25] Cullen PA, Haake DA, Adler B. Outer membrane proteins of pathogenic
spirochetes. FEMS Microbiol Rev 2004;28(3):291–318.
[26] Branger C, Sonrier C, Chatrenet B, Klonjkowski B, Ruvoen-Clouet N,
Aubert A, et al. Identification of the hemolysis-associated protein 1 as a
cross-protective immunogen of Leptospira interrogans by adenovirus-
mediated vaccination. Infect Immun 2001;69(11):6831–8.
[27] Haake DA, Mazel MK, McCoy AM, Milward F, Chao G, Matsunaga J,
et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit
synergistic immunoprotection. Infect Immun 1999;67(12):6572–82.
[28] Branger C, Chatrenet B, Gauvrit A, Aviat F, Aubert A, Bach JM, et al.
Protection against Leptospira interrogans sensu lato challenge by DNA
immunization with the gene encoding hemolysin-associated protein 1.
Infect Immun 2005;73(7):4062–9.
[29] Koizumi N, Watanabe H. Leptospiral immunoglobulin-like proteins
elicit protective immunity. Vaccine 2004;22(11–12):1545–52.
[30] Matsunaga J, Barocchi MA, Croda J, Young TA, Sanchez Y, Siqueira I,
et al. Pathogenic Leptospira species express surface-exposed proteins
belonging to the bacterial immunoglobulin superfamily. Mol Microbiol
2003;49(4):929–45.
[31] Palaniappan RU, Chang YF, Jusuf SS, Artiushin S, Timoney JF,
McDonough SP, et al. Cloning and molecular characterization of an
immunogenic LigA protein of Leptospira interrogans. Infect Immun
2002;70(11):5924–30.
[32] Palaniappan RU, Chang YF, Hassan F, McDonough SP, Pough M, Barr
SC, et al. Expression of leptospiral immunoglobulin-like protein by
Leptospira interrogans and evaluation of its diagnostic potential in a
kinetic ELISA. J Med Microbiol 2004;53(10):975–84.
[33] Choy HA, Kelley MM, Chen TL, Moller AK, Matsunaga J, Haake DA.
Physiological osmotic induction of Leptospira interrogans adhesion:
LigA and LigB bind extracellular matrix proteins and fibrinogen. Infect
Immun 2007;75(5):2441–50.
[34] Viriyakosol S, Matthias MA, Swancutt MA, Kirkland TN, Vinetz
JM. Toll-like receptor 4 protects against lethal Leptospira interrogans
serovar icterohaemorrhagiae infection and contributes to in vivo control
of leptospiral burden. Infect Immun 2006;74(2):887–95.
[35] Palaniappan RU, McDonough SP, Divers TJ, Chen CS, Pan MJ,
Matsumoto M, et al. Immunoprotection of recombinant leptospiral
immunoglobulin-like protein A against Leptospira interrogans serovar
Pomona infection. Infect Immun 2006;74(3):1745–50.
[36] Nascimento AL, Ko AI, Martins EA, Monteiro-Vitorello CB, Ho PL,
Haake DA, et al. Comparative genomics of two Leptospira interro-
gans serovars reveals novel insights into physiology and pathogenesis.
J Bacteriol 2004;186(7):2164–72.
[37] World Health Organization. Human leptospirosis: guidance for diagno-
sis, surveillance and control. Malta: World Health Organization; 2003.
[38] Crowther JR. ELISA. Theory and practice. Methods Mol Biol
1995;42:1–218.
[39] Matsunaga J, Sanchez Y, Xu X, Haake DA, Osmolarity. a key
environmental signal controlling expression of leptospiral proteins
LigA and LigB and the extracellular release of LigA. Infect Immun
2005;73(1):70–8.
[40] Reed LJ, Muench H. A simple method of estimating fifty percent end-
points. Am J Hyg 1938;27:493–7.
[41] Chappel RJ, Prime RW, Millar BD, Mead LJ, Jones RT, Adler B.
Comparison of diagnostic procedures for porcine leptospirosis. Vet
Microbiol 1992;30(2–3):151–63.
[42] Adler B, Faine S. Susceptibility of mice treated with cyclophosphamide
to lethal infection with Leptospira interrogans Serovar pomona. Infect
Immun 1976;14(3):703–8.
[43] Adler B, Faine S. Host immunological mechanisms in the resistance of
mice to leptospiral infections. Infect Immun 1977;17(1):67–72.
[44] Naiman BM, Blumerman S, Alt D, Bolin CA, Brown R, Zuerner R,
et al. Evaluation of type 1 immune response in naive and vaccinated
animals following challenge with Leptospira borgpetersenii serovar
Hardjo: involvement of WC1(+) gammadelta and CD4 T cells. Infect
Immun 2002;70(11):6147–57.
[45] Wiwanitkit V. Predicted epitopes of Lig A of Leptospira interrogans by
bioinformatics method: a clue for further vaccine development. Vaccine
2007;25(15):2768–70.
[46] Ido Y, Hoki R, Ito H, Wani H. The prohylaxis of Weil’s dis-
ease (Spirochaetosis icterohaemorrhagica). J Exp Med 1916;24:471–
83.
[47] Bulach DM, Zuerner RL, Wilson P, Seemann T, McGrath A,
Cullen PA, et al. Genome reduction in Leptospira borgpetersenii
reflects limited transmission potential. Proc Natl Acad Sci USA
2006;103(39):14560–5.
[48] Ren SX, Fu G, Jiang XG, Zeng R, Miao YG, Xu H, et al. Unique physi-
ological and pathogenic features of Leptospira interrogans revealed by
whole-genome sequencing. Nature 2003;422(6934):888–93.